 | |
 Vaxart's HQ located in South San Francisco | |
| Company type | Public |
|---|---|
| Nasdaq: VXRT | |
| Industry | Biotechnology |
| Founded | 2004 |
| Founder | Sean Tucker |
| Headquarters | South San Francisco, California |
Key people | Steven Lo (CEO) |
| Products | Oral vaccines |
| Revenue |  US $7.38 million (2023) |
 US -$82.4 million (2023) | |
Number of employees | 109 (2023) |
| Website | vaxart |
| Footnotes / references [1] | |
Vaxart, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of oral recombinant vaccines administered using temperature-stable tablets that can be stored and shipped without refrigeration, eliminating the need for needle injection. Its development programs for oral vaccine delivery (Vector-Adjuvant-Antigen Standardized Technology known as VAAST) include prophylactic, enteric-coated tablet vaccines for inhibiting norovirus, seasonal influenza, respiratory syncytial virus, and human papillomavirus. It was founded in 2004 by Sean Tucker.[2] Originally incorporated as West Coast Biologicals, Inc. in California in 2004, the company later changed its name to Vaxart, Inc. in July 2007, after reincorporating in Delaware. A significant development in the company's history was the reverse merger with Aviragen Therapeutics, Inc. on February 13, 2018, which led to Vaxart becoming a wholly-owned subsidiary of Aviragen. Post-merger, the company continued as Vaxart, Inc.[3]
Vaxart's development portfolio includes a range of oral vaccines targeting infectious diseases such as norovirus, COVID-19, and seasonal influenza, as well as therapeutic vaccines like those targeting HPV. The company has achieved significant milestones in its vaccine development, including completing Phase 1 trials for its COVID-19 vaccine candidate and embarking on Phase 2 studies. Vaxart’s vaccines are designed to elicit not only systemic immune responses but also mucosal and T cell responses, which may enhance protection against specific diseases and offer potential benefits for certain cancers and chronic viral infections. The tablet form of these vaccines represents a significant advancement in vaccine administration, potentially improving patient acceptance and resolving distribution challenges.[4]
- ^ "FORM 10-K". December 31, 2023. Retrieved July 12, 2024.
- ^ Leuty, Ron (August 6, 2013). "Flu vaccine developer Vaxart snags $20 million". www.bizjournals.com. Retrieved 2022-01-09.
- ^ "Vaxart Inc. Closes Merger with Aviragen Therapeutics, Inc". Business Wire. February 13, 2018. Retrieved January 29, 2024.
- ^ "Vaxart, Inc. 2023 10-K Filing". Vaxart, Inc. March 15, 2023. Retrieved January 29, 2024.